ReviewInternational journal of emergency medicine2025
Stem cell therapies and glioma stem cells in glioblastoma: a systematic review of current challenges and research directions.
Review in International journal of emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Advances in glioblastoma: Is there light at the end of the tunnel?The Indian journal of medical research · 2026Article
- Computational design and immunoinformatics validation of a T cell multi-epitope vaccine targeting glioblastoma stem cells.Scientific reports · 2026Article
- Review
- The impact of inhibiting the Hippo signaling pathway effector molecule YAP1 on in vitro glioblastoma and glioblastoma stem cells.Scientific reports · 2026Article
- Preoperative embolization for glioblastoma surgery: A scoping review.Surgical neurology international · 2026Review
- Global, regional, and national childhood brain and central nervous system cancer burden: an analysis based on the Global Burden of Disease Study.Tropical medicine and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma is the most aggressive tumor of glial origin and the most common, as established by the World Health Organization. GBM has been one of the most intractable tumors with minimal progress in prognosis despite decades of research. Stem cell therapy (SCT) has raised hopes with regard to possibly targeting tumor progression and recurrence. Glioma stem cells (GSCs) are directly involved in gliomagenesis and chemoresistance, thus constituting potential valuable therapeutic targets for improving treatment outcomes.
objectiveThe objective of this review article is to assess and consider the potential therapeutic benefits, challenges, and prospective research directions for SCTs for glioblastoma with a particular focus on GSCs as key therapeutic targets. MATERIALS AND
methodsA literature review was performed using search terms and Boolean operators pertinent to SCT and glioblastomas to gather all existing literature. The databases PubMed/MEDLINE, Scopus, and the Cochrane Library were searched in accordance with the standard guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020. RESULTS AND
conclusionsThe review established that the main mesenchymal stem cells (MSCs), neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and hematopoietic stem cells are the first SCTs evaluated in terms of their potential as a glioblastoma therapy. While SCTs were found to be effective in tumor targeting and immune modulation, they face certain restrictions, including death of stem cells inside the body, tumor heterogeneity, and transformation to malignancy. Research must now focus on the combination of stem cell therapy with molecular-targeted therapy and advanced delivery systems for improved tumor targeting, better overcoming resistance, and enhancing both efficacy and safety for patients undergoing treatment for glioblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.